Skip to main content
Fig. 5 | Cardio-Oncology

Fig. 5

From: Use of integrated imaging and serum biomarker profiles to identify subclinical dysfunction in pediatric cancer patients treated with anthracyclines

Fig. 5

Plasma profiling changes from Visit 1 to last available visit in AC treated patients. The relative change in ECM and inflammatory pathways were computed as a function of Visit 1 and the final visit in the AC treated patients. Those with a significant shift from Visit 1 are shown here and identify that continued shifts in determinants of inflammatory signaling and ECM remodeling occurred at later AC treatment time points. (*p < 0.05 vs Visit 1 values)

Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us